Addus HomeCare Co. (NASDAQ:ADUS - Get Free Report)'s share price traded down 6.1% during mid-day trading on Tuesday . The company traded as low as $117.27 and last traded at $121.10. 21,713 shares traded hands during trading, a decline of 83% from the average session volume of 130,611 shares. The stock had previously closed at $128.96.
Wall Street Analyst Weigh In
Several equities analysts have commented on ADUS shares. Oppenheimer boosted their price target on shares of Addus HomeCare from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Monday, September 23rd. Royal Bank of Canada restated an "outperform" rating and set a $141.00 price target on shares of Addus HomeCare in a report on Tuesday, September 3rd. Stephens reissued an "overweight" rating and set a $138.00 price objective on shares of Addus HomeCare in a research report on Tuesday, August 6th. Macquarie restated an "outperform" rating and set a $139.00 target price on shares of Addus HomeCare in a research note on Monday. Finally, TD Cowen lifted their price target on shares of Addus HomeCare from $128.00 to $137.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $131.38.
View Our Latest Research Report on Addus HomeCare
Addus HomeCare Trading Down 3.7 %
The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of 28.13, a price-to-earnings-growth ratio of 2.29 and a beta of 1.04. The company's 50 day moving average is $129.93 and its 200 day moving average is $120.66.
Addus HomeCare (NASDAQ:ADUS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $1.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.02. Addus HomeCare had a return on equity of 9.81% and a net margin of 6.18%. The firm had revenue of $289.80 million during the quarter, compared to analysts' expectations of $289.42 million. During the same period in the prior year, the firm earned $1.03 EPS. The business's revenue was up 7.1% on a year-over-year basis. Analysts anticipate that Addus HomeCare Co. will post 4.57 EPS for the current fiscal year.
Insider Transactions at Addus HomeCare
In other Addus HomeCare news, EVP Michael D. Wattenbarger sold 21,917 shares of Addus HomeCare stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $133.29, for a total value of $2,921,316.93. Following the transaction, the executive vice president now directly owns 7,215 shares in the company, valued at approximately $961,687.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael D. Wattenbarger sold 21,917 shares of Addus HomeCare stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $133.29, for a total value of $2,921,316.93. Following the sale, the executive vice president now owns 7,215 shares of the company's stock, valued at $961,687.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Esteban Lopez sold 500 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total transaction of $63,750.00. Following the transaction, the director now directly owns 3,366 shares of the company's stock, valued at $429,165. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,917 shares of company stock worth $3,050,082. Company insiders own 4.60% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. UMB Bank n.a. increased its stake in Addus HomeCare by 64.2% in the 2nd quarter. UMB Bank n.a. now owns 225 shares of the company's stock valued at $26,000 after purchasing an additional 88 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Addus HomeCare during the 2nd quarter worth $31,000. EntryPoint Capital LLC purchased a new position in shares of Addus HomeCare in the 1st quarter worth about $44,000. Innealta Capital LLC purchased a new stake in shares of Addus HomeCare during the 2nd quarter worth about $44,000. Finally, Farther Finance Advisors LLC increased its position in Addus HomeCare by 9,150.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 370 shares of the company's stock worth $49,000 after purchasing an additional 366 shares in the last quarter. Institutional investors and hedge funds own 95.35% of the company's stock.
Addus HomeCare Company Profile
(
Get Free Report)
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.
Featured Articles
Before you consider Addus HomeCare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Addus HomeCare wasn't on the list.
While Addus HomeCare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.